Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.
about
Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complexExploiting viral natural history for vaccine developmentCytomegalovirus: pathogen, paradigm, and puzzleIsolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cellsCytomegalovirus reinfections in healthy seroimmune women.Using the nonhuman primate model of HCMV to guide vaccine developmentAntibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infectionDesign and analysis of rhesus cytomegalovirus IL-10 mutants as a model for novel vaccines against human cytomegalovirusPrevention of maternal cytomegalovirus infection: current status and future prospects.Host immune responses to a viral immune modulating protein: immunogenicity of viral interleukin-10 in rhesus cytomegalovirus-infected rhesus macaques.Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibodyRecent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases.Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infectionVaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodiesPeptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cellsAnti-cytomegalovirus activity of the anthraquinone atanyl blue PRL.A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell typesNeutralizing activity of saliva against cytomegalovirus.Modeling of human cytomegalovirus maternal-fetal transmission in a novel decidual organ cultureBacterial artificial chromosome clones of viruses comprising the towne cytomegalovirus vaccine.A Homolog Pentameric Complex Dictates Viral Epithelial Tropism, Pathogenicity and Congenital Infection Rate in Guinea Pig CytomegalovirusVaccination with a Live Attenuated Cytomegalovirus Devoid of a Protein Kinase R Inhibitory Gene Results in Reduced Maternal Viremia and Improved Pregnancy Outcome in a Guinea Pig Congenital Infection Model.The Cellular Localization of Human Cytomegalovirus Glycoprotein Expression Greatly Influences the Frequency and Functional Phenotype of Specific CD4+ T Cell Responses.Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.Cytomegalovirus vaccines and methods of production (WO20009049138): the emerging recognition of the importance of virus neutralization at the epithelial/endothelial interfaceGuinea Pig Cytomegalovirus (GPCMV): A Model for the Study of the Prevention and Treatment of Maternal-Fetal Transmission.A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection.A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.Update on the current status of cytomegalovirus vaccines.Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.Alveolar Macrophages Are a Prominent but Nonessential Target for Murine Cytomegalovirus Infecting the LungsIn Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.Antibody inhibition of human cytomegalovirus spread in epithelial cell culturesA Novel Non-Replication-Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection.Repair of a Mutation Disrupting the Guinea Pig Cytomegalovirus Pentameric Complex Acquired during Fibroblast Passage Restores Pathogenesis in Immune-Suppressed Guinea Pigs and in the Context of Congenital Infection.Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells.Cytomegalovirus vaccines.
P2860
Q21089588-EB1320E1-9E2E-4B45-9A51-93FE491A389EQ28081817-3ED61FE2-5C62-413E-AE61-EA9312008879Q33351523-C6D9667C-3C17-4156-BA18-40D17E47322DQ33558361-717B3F7E-3E4C-41E8-8DAF-51B7975A1F3CQ33558900-14E5909A-3EE3-4EEA-85D4-604947BD5FEBQ33583493-794F2238-67B7-4B42-AA5D-CBBEF1CEB69EQ33584739-D184AA24-FA1B-4976-8CC1-B11FEE7979A1Q34086932-C3BC3A7A-AFD9-46AB-8284-CFC8CE90F3E9Q34088164-AB1A9061-16C3-4798-B5B0-BBF210E68E04Q34272089-DAA375A6-7779-471F-AE39-89E0B649DF4CQ34289143-9894D63A-F7BD-4C9D-8703-6550AE3DC053Q34317887-3D694906-E18A-4281-B9E8-1A0AC59CF976Q34349745-8D8A3F08-EE92-4ACE-A12D-AA3A13E87C82Q34652466-FF6D254B-2F80-481C-A7D8-FE9756AA5FBCQ34742892-785E4D48-9048-45AB-8759-9F4965B26AE4Q34753135-0A15231C-B17C-4ECC-AC30-6CE1B5E339D1Q34885758-82382F9B-5BFA-4359-A447-99BE224F4865Q34902453-D0B28DF0-9D26-47C9-B14E-83F26C768A27Q35076970-6285F6AE-E73E-4C81-B8F5-EAB614D0F9B5Q35191120-063A4615-166E-4577-9BA1-8661A36CDBABQ35599273-AF71B67F-64FF-49B5-ABF2-FB02037346EDQ35609192-09CFD82F-F5B9-4368-9A14-4BA2E1D2F78AQ36069719-C314F08E-C3E0-478A-800D-9CB2FA4AE10DQ36080805-8F13934E-0A6E-4DB4-B332-93FFCC6A41FFQ36116754-06C069F0-921C-4456-AE8D-1DDEAEE833E2Q36281094-C1826E78-E430-4E21-86F1-7AB388157271Q36385141-7ECF6BB2-3602-4C8F-B1F6-D05A22C8026FQ36517096-65C02678-1591-47CE-833A-9ED8F63D1F0BQ36517126-510D4C9D-6C59-4153-A74A-EA765249E928Q36517130-9182AD29-79B7-44AC-AD72-8714DA0B5603Q36559845-B992DEBE-3516-4F3D-83B1-1215597911A9Q36678423-AB3DC906-0B15-43E3-B27F-63C8CC70CD01Q36694861-348758E1-D154-4754-8264-96D47C9CF423Q36736688-3ADE3D23-8D7D-484B-B9EE-6F0E8B35DA07Q37120061-45916A44-1382-4081-91E4-AF7DDB14186EQ37174327-ED39D949-70E7-4C74-8A02-82A3D97D39ACQ37182670-3ED9CDD7-DFE0-472A-ABC1-C86F1EFB61B5Q37182699-D1D75DB7-758B-4EF2-ACF6-225C59752714Q37252609-9C4552F4-D699-49E8-B899-D35EC89A8601Q37332494-B1776B1F-932B-4718-9D06-2209E0EB209B
P2860
Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Cytomegalovirus vaccines fail ...... mparable to natural infection.
@en
type
label
Cytomegalovirus vaccines fail ...... mparable to natural infection.
@en
prefLabel
Cytomegalovirus vaccines fail ...... mparable to natural infection.
@en
P2093
P2860
P1433
P1476
Cytomegalovirus vaccines fail ...... mparable to natural infection.
@en
P2093
Benjamin P Meza
Michael A McVoy
Stuart P Adler
Xiaohong Cui
P2860
P304
P356
10.1016/J.VACCINE.2008.07.092
P407
P577
2008-08-19T00:00:00Z